Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the
superfamily of serine protease inhibitors, serpins. It was first identified as a neuronal differentiating
factor secreted by human retinal pigment epithelial cells, and then found to be
the most potent inhibitor of pathological angiogenesis in mammalian eyes. Recently,
PEDF has been shown not only to suppress oxidative stress and inflammatory reactions in
vascular wall cells, T cells and macrophages, and adipocytes, but also to exert antithrombotic
and anti-fibrotic properties, thereby protecting against the development and
progression of various cardiometabolic diseases and related complications. Furthermore,
accumulating evidence has suggested that circulating PEDF levels may be a biomarker of
severity and prognosis of these devastating disorders. Number of subjects with visceral
obesity and insulin resistance is increasing, and the metabolic syndrome and its related
complications, such as diabetes, nonalcoholic fatty liver disease/non-alcoholic steatohepatits,
and atherosclerotic cardiovascular disease are a growing health challenge. Therefore,
in this study, we review the pathophysiological role of PEDF in obesity and metabolic
disorders, cardiovascular disease, diabetic eye and kidney complications, liver diseases,
and reproductive system disorders, and discuss the potential clinical utility of modulating
the expression and actions of PEDF for preventing these cardiometabolic disorders. We
also refer to the clinical value of PEDF as a biomarker in cardiometabolic complications.
Increased levels of serum pigment epithelium-derived factor aggravate proteinuria via induction of podocyte actin rearrangement
